中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

66 records (took 0.066 seconds)

    Gene and Polypeptide Sequences
    52.
    发明申请
    Gene and Polypeptide Sequences 有权
    基因和多肽序列

    公开(公告)号：US20130059785A1

    公开(公告)日：2013-03-07

    申请号：US13569697

    申请日：2012-08-08

    Applicant: Darrell Sleep

    Inventor： Darrell Sleep

    IPC: C07K19/00 ,  C12N15/80 ,  C12N1/15 ,  A61P7/00 ,  C12P21/02 ,  A61K38/38 ,  A61K38/40 ,  A61P17/02 ,  C12N15/62 ,  C12N1/19

    CPC classification number: C07K14/765 ,  C07K14/79 ,  C07K2319/02 ,  C12N15/625 ,  C12N15/81

    Abstract: The present invention provides a polypeptide comprising (i) a leader sequence, the leader sequence comprising a (a) secretion pre sequence, and (b) the following motif: -X1-X2-X3-X4-X5- where X1 is phenylalanine, tryptophan, or tyrosine, X2 is isoleucine, leucine, valine, alanine or methionine, X3 is leucine, valine, alanine or methionine, X4 is serine or threonine and X5 is isoleucine, valine, alanine or methionine; and (ii) a desired protein heterologous to the leader sequence. A polypeptide of the invention may additionally comprise, as part of the leader sequence, a secretion pro sequence. The invention also provides a polynucleotide comprising a sequence that encodes a polypeptide of the invention and a cell, preferably a yeast cell, comprising said polynucleotide.

    Abstract translation: 本发明提供一种多肽，其包含（i）前导序列，前导序列包含（a）分泌前序列，和（b）以下基序：-X1-X2-X3-X4-X5-，其中X1是苯丙氨酸， 缬氨酸，丙氨酸或甲硫氨酸，X4为丝氨酸或苏氨酸，X5为异亮氨酸，缬氨酸，丙氨酸或甲硫氨酸; X 4为异亮氨酸，缬氨酸，丙氨酸或甲硫氨酸， 和（ii）与前导序列异源的所需蛋白质。 作为前导序列的一部分，本发明的多肽可另外包含分泌原序列。 本发明还提供了包含编码本发明多肽的序列和包含所述多核苷酸的细胞，优选酵母细胞的多核苷酸。

    Albumin-Fused Anti-Angiogenesis Peptides
    53.
    发明申请
    Albumin-Fused Anti-Angiogenesis Peptides 审中-公开
    白蛋白融合抗血管生成肽

    公开(公告)号：US20120263747A1

    公开(公告)日：2012-10-18

    申请号：US13285727

    申请日：2011-10-31

    Applicant: Peter Mertins ,  Ilhan Celik ,  Oliver Kisker ,  Darrell Sleep ,  Joanna Hay ,  Hans-Peter Hauser

    Inventor： Peter Mertins ,  Ilhan Celik ,  Oliver Kisker ,  Darrell Sleep ,  Joanna Hay ,  Hans-Peter Hauser

    IPC: C07K19/00 ,  A61P9/10 ,  A61P9/00 ,  A61K39/385 ,  A61K48/00 ,  A61P37/04 ,  A61P29/00 ,  A61P19/02 ,  A61P17/06 ,  A61P27/02 ,  A61P1/00 ,  A61P17/00 ,  A61P17/02 ,  A61P1/04 ,  A61K38/38

    CPC classification number: A61K38/39 ,  A01K2217/05 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0005 ,  A61K47/643 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/005 ,  C07K14/47 ,  C07K14/765 ,  C07K14/78 ,  C07K14/8114 ,  C07K2319/00 ,  C07K2319/31 ,  C12N15/62 ,  C12N2740/16122 ,  C12Y301/26003

    Abstract: The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis.

    Abstract translation: 本发明涉及包含血管生成抑制肽（例如内皮抑素肽（包括但不限于其片段和变体））的蛋白质，其表现出与白蛋白融合或缀合的抗逆转录病毒活性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及抑制血管内皮细胞增殖和肿瘤发生生成诱导的细胞融合的组合物和方法。 本发明还涉及预防原发性肿瘤和转移瘤的生长或促进消退的组合物和方法; 并用于治疗癌症，糖尿病性视网膜病变，进行性黄斑变性或类风湿性关节炎。

    Gene Expression Technique
    54.
    发明申请
    Gene Expression Technique 审中-公开
    基因表达技术

    公开(公告)号：US20120231503A1

    公开(公告)日：2012-09-13

    申请号：US13474317

    申请日：2012-05-17

    Applicant: Darrell Sleep ,  Gillian Shuttleworth ,  Christopher John Arthur Finnis

    Inventor： Darrell Sleep ,  Gillian Shuttleworth ,  Christopher John Arthur Finnis

    IPC: C12P21/00 ,  C12P21/08 ,  C12N9/72 ,  C12N1/19 ,  C12N9/50 ,  C12N9/04 ,  C12N9/18 ,  C12N15/63 ,  C12N9/74

    CPC classification number: C12N15/80

    Abstract: The present disclosure relates to a method for producing heterologous protein including: (c) providing a host cell comprising a 2 μm-family plasmid, the plasmid comprising a gene encoding a protein comprising the sequence of a chaperone protein and a gene encoding a heterologous protein; (d) culturing the host cell in a culture medium under conditions that allow the expression of the gene encoding the chaperone protein and the gene encoding a heterologous protein; (e) purifying the thus expressed heterologous protein from the cultured host cell or the culture medium.

    Abstract translation: 本公开内容涉及用于产生异源蛋白质的方法，包括：（c）提供包含2μm家族质粒的宿主细胞，所述质粒包含编码包含伴侣蛋白序列的蛋白质的基因和编码异源蛋白质的基因 ; （d）在允许表达编码伴侣蛋白的基因和编码异源蛋白质的基因的条件下，在培养基中培养宿主细胞; （e）从培养的宿主细胞或培养基纯化如此表达的异源蛋白质。

    Albumin-Fused Kunitz Domain Peptides
    57.
    发明申请
    Albumin-Fused Kunitz Domain Peptides 审中-公开
    白蛋白融合Kunitz结构域肽

    公开(公告)号：US20110092413A1

    公开(公告)日：2011-04-21

    申请号：US12917903

    申请日：2010-11-02

    Applicant: Hans-Peter Hauser ,  Thomas Weimer ,  Val Romberg ,  Scott M. Kee ,  Darrell Sleep ,  Robert Charles Ladner ,  Arthur C. Ley

    Inventor： Hans-Peter Hauser ,  Thomas Weimer ,  Val Romberg ,  Scott M. Kee ,  Darrell Sleep ,  Robert Charles Ladner ,  Arthur C. Ley

    IPC: C07K14/76 ,  A61K38/38 ,  A61P11/00 ,  C12N15/62 ,  C12N15/63 ,  C12N1/00 ,  C12P21/02

    CPC classification number: C12N15/62 ,  C07K2319/31

    Abstract: The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules and vectors encoding the albumin fusion proteins of the invention, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer.

    Abstract translation: 本发明涉及包含丝氨酸蛋白酶抑制肽的蛋白质，例如与白蛋白或其片段或变体融合的Kunitz结构域肽（包括但不限于其片段和变体）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白，用这些核酸和载体转化的宿主细胞的核酸分子和载体，以及使用这些核酸，载体和/或宿主制备本发明的白蛋白融合蛋白的方法 细胞。 本发明还涉及抑制嗜中性粒细胞弹性蛋白酶，激肽释放酶和纤溶酶的组合物和方法。 本发明还涉及治疗囊性纤维化和癌症的组合物和方法。

    Interleukin-11 Fusion Proteins
    58.
    发明申请
    Interleukin-11 Fusion Proteins 审中-公开
    白细胞介素-11融合蛋白

    公开(公告)号：US20100143973A1

    公开(公告)日：2010-06-10

    申请号：US12626107

    申请日：2009-11-25

    Applicant: Monika Kröz ,  Gerhard Dickneite ,  Hans-Peter Hauser ,  Thomas Weimer ,  Darrell Sleep

    Inventor： Monika Kröz ,  Gerhard Dickneite ,  Hans-Peter Hauser ,  Thomas Weimer ,  Darrell Sleep

    IPC: C07K19/00 ,  C12P21/00 ,  C12N5/10 ,  C12N1/21 ,  C12N1/15 ,  C12N1/19 ,  C12N15/63 ,  C07H21/04 ,  C07K14/54

    CPC classification number: A61K38/38 ,  A61K38/2073 ,  C07K14/5431 ,  C07K14/76 ,  C07K14/765 ,  C07K2319/31 ,  Y02A50/473

    Abstract: The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or anti-inflammatory properties, fused to albumin (including, but not limited to, fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.

    Abstract translation: 本发明涉及包含白细胞介素11（IL-11）（包括但不限于其片段和变体）的蛋白质，其表现出与白蛋白融合的血小板生成或抗炎特性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。

Patent Agency Ranking